Cancer of Head and Neck, CT Scan, Sarcopenia
Conditions
Brief summary
Sarcopenia is defined by the reduction in skeletal muscle mass and physical performance. It results in a decrease in muscle strength, overall physical activity, walking and the development of balance disorders and falls. It is one of the natural consequences of aging and contributes to frailty and the appearance of geriatric syndrome (s) (Chandapasirt et al, 2015; Cruz-Jentoft et al, 2010). Its prevalence in patients with Head & Neck cancer is 39% (Hua et al, 2020) and is associated with an increase in postoperative complications (Achim et al, 2017; Bril et al, 2019), with greater toxicity of chemotherapy. (Wendrich et al, 2017) and reduced overall survival (Hua et al, 2020). It is measured by CT scan (assessment of muscle volume with respect to L3 using IMAGE J software) (Teigen et al, 2018) and by clinical tests (performance tests) (Swartz et al, 2016, Cruz-Jentoft et al, 2010). Several studies have shown a possible assessment of sarcopenia by measuring skeletal muscle mass with regard to C3 (Ufuk et al, 2019; Swartz et al, 2016). This trial aims to evaluate the prevalence of sarcopenia in head and neck cancer evaluated by CT at C3.
Interventions
evaluation of sarcopenia by CT san at the C3 vertebrae
Sponsors
Weprom
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* patient over 18 years old, * affiliated to the social security scheme, * suffering from locally advanced head & neck cancer (stages I to IVB) at diagnosis, * not operable, * justifying treatment by radiotherapy, whether or not associated with chemotherapy or targeted therapy (eg: monoclonal antibodies, immunotherapy) whatever the proposed modalities.
Exclusion criteria
* patient treated by non-conservative surgery and cervical lymph node dissection making it impossible to assess muscle mass with regard to C3, * metastatic disease, * minor patient, * adult patient under guardianship, * pregnancy or breastfeeding in progress.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Assessment of the prevalence of sarcopenia by cervical CT scan (C3) | 6 months | Number of patients with sarcopenia at diagnosis and during treatments |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Assessment of hypoalbuminemia | 6 month | Number of patients presenting an hypoalbuminemia. |
| De- and undernutrition | 6 month | Number of patients with a BMI \<18 and with a prescription for nutritional complements. |
| Compliance to the treatment | 6 months | Number of patients having the complete planned treatment |
| complete response rate | 6 months | Number of patients with a complete response on the end-of-treatment evaluation scanner according to the RECIST or PERCIST criteria in the numerator out of the total number of patients in the denominator |
| Assessment of hospitalizations treatment-related complications | 6 months | Number of hospitalizations per patient for treatment-related complications |
Countries
France
Contacts
Primary ContactMagali BALAVOINE
Backup ContactJonas DUBU
Outcome results
None listed